Medicenna Therapeutics (TSE:MDNA) Trading 17.8% Higher - Should You Buy?

Key Points

• Medicenna Therapeutics shares surged by 17.8% to C$1.19, trading volume increased by 719% compared to the average session.
• The company, with a market capitalization of C$89.03 million, specializes in immuno-oncology and is focused on developing treatments targeting the Interleukin-4 Receptor found in various cancers.
• Medicenna has negative earnings with a P/E ratio of -3.28, indicating challenges in profitability despite the recent stock price rise.

Medicenna Therapeutics Corp. (TSE:MDNA - ) shares traded up 17.8% on Friday . The stock traded as high as C$1.19 and last traded at C$1.19. 379,355 shares were traded during trading, an increase of 719% from the average session volume of 46,327 shares. The stock had previously closed at C$1.01.

Medicenna Therapeutics Trading Up 17.8%

The firm has a market capitalization of C$89.03 million, a P/E ratio of -3.28 and a beta of 1.21. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40. The firm has a 50 day moving average price of C$0.88 and a two-hundred day moving average price of C$1.02.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.